Every January, millions of Americans on Medicare sit down with their prescription drug plans and wonder: what will this cost me this year? It was no different in 2025, the first year a brand-new law took full effect. But the surprise this time, according to a new study published in the journal Health Affairs, was good news wrapped in a twist.
A team led by David Anderson, a health services policy professor, wanted to see how insurance companies would react to the 2022 Inflation Reduction Act. That law did something historic: it capped what seniors pay out of pocket for their prescription drugs at $2,000 a year. In 2024 the cap was $3,800. Before 2023, there was no cap at all — a person could owe endless amounts.
So the big fear was that insurers would punish beneficiaries to make up for their extra risk. After past policy changes, companies have typically done three things: pull out of the market, raise premiums, or quietly make their plans stingier. Would that happen again? Anderson and his colleagues compared the first year of real data against what things would have looked like without the law.
Here is what they found. Premiums actually went down a bit, so monthly bills were lower than expected and quite affordable. But deductibles jumped up — even more than the researchers predicted. That means seniors in many plans faced higher upfront costs before their coverage kicked in. Drug coverage also got slightly tighter, with some cheaper, preferred medications no longer offered. And the number of available plans shrank, meaning a few insurers simply chose to leave the market.
Yet here is the reassuring part. Even with those shifts, the new $2,000 out-of-pocket cap held steady in year one, giving beneficiaries real and measurable relief. Anderson notes that most of the changes were just moving money around. "Insurers appear to be rebalancing their plans by shifting beneficiary costs from monthly payments to upfront payments," he said.
Crucially, insurers did not do the worst thing they could have — designing plans to avoid people with expensive drug needs. "We expected more significant alterations to plan designs," Anderson said, "but we have not seen that shift so far."
Part of the reason costs stayed low is how the law shares the bill after that $2,000 cap is reached. Insurers' responsibility jumped from 20% to 60% of the cost, while the government's share fell from 80% to 20%, and drug manufacturers now cover the remaining fifth.
The message for seniors is hopeful but cautious. One good year doesn't guarantee the next. Anderson stresses that the market needs watching, because insurers may change tactics as the rules evolve. For now, though, the cap that so many Americans worried about has delivered its first-year promise — real relief from shocking drug bills.